Zevra Therapeutics Revenue Jumps 53% Driven by Miplyffa Sales

Key Facts

1Zevra achieved net revenue of $39.7M in 2Q26, a 53% year-over-year increase.

2The drug Miplyffa contributed $30.2M to total revenue as the addressable market continues to expand.

Zevra Therapeutics achieved net revenue of $39.7 million in the second quarter of 2026, marking a 53% increase year-over-year. Seeking Alpha reported that the drug Miplyffa contributed $30.2 million to the total revenue as the company's addressable market continues to expand.

ZVRA closed at $10.7 on October 5, 2026, with the stock reaching a day high of $10.81 and a low of $10. The financial performance is driven by high patient retention and management's efforts to expand the addressable market for Niemann-Pick disease type C to 900 patients.